482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Onilcamotide Prostate Cancer	RhoVac APS	P2	CCC (53)
Osimertinib Prostate Cancer	OHSU Knight Cancer Institute	P2	CCC (53)
Palbociclib Prostate Cancer	OHSU Knight Cancer Institute	P2	CCC (53)
Pamiparib Prostate Cancer	The First Affiliated Hospital of Xiamen University	P2	CCC (53)
Povidone-Iodine Prostate Cancer	Hitit University	P2	CCC (53)
Technetium Tc-99M Cation, Unspecified Prostate Cancer	University of California, San Francisco	P2	CCC (53)
Terbinafine Prostate Cancer	Swiss Cancer Institute	P2	CCC (53)
Teverelix Dp Prostate Cancer	Antev Ltd.	P2	CCC (53)
Tuvusertib Prostate Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Valemetostat Prostate Cancer	Alliance for Clinical Trials in Oncology	P2	CCC (53)
Zopocianine Prostate Cancer	Clinton Bahler	P2	CCC (53)
Copper Cu 64 Psma I Prostate Cancer	Curium US LLC	P3	CCC (52)
Decitabine Prostate Cancer	Roswell Park Cancer Institute	P1/2	CCC (52)
Eflornithine Prostate Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (52)
Fludarabine Prostate Cancer	Beijing Biotech	P2	CCC (52)
Fluorouracilum Prostate Cancer	Parabilis Medicines, Inc.	P1/2	CCC (52)
Hrs-5041 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CCC (52)
Ketorolac Prostate Cancer	Wake Forest University Health Sciences	P2/3	CCC (52)
Luteinizing Hormone-Releasing Hormone Prostate Cancer	H. Lee Moffitt Cancer Center and Research Institute	P3	CCC (52)
Rituximab Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)
Ruxolitinib Prostate Cancer	University of Michigan Rogel Cancer Center	P2	CCC (52)
Niraparib Prostate Cancer	Latin American Cooperative Oncology Group	P2	CCC (51)
Nogapendekin Alfa Inbakicept Prostate Cancer	National Cancer Institute (NCI)	P2	CCC (51)
Pantoprazole Prostate Cancer	Fred Hutchinson Cancer Center	P2	CCC (51)
Prothrombin Complex Concentrate Prostate Cancer	Konkuk University Medical Center	P4	CCC (51)
Vorinostat Prostate Cancer	Fred Hutchinson Cancer Center	P2	CCC (51)
[18f]psma-pet Prostate Cancer	Region Västerbotten	P3	CCC (50)
64cu-dota-ae105 Prostate Cancer	Curasight	P2	CCC (50)
asp5541 Prostate Cancer	Astellas Pharma Global Development, Inc.	P2	CCC (50)
bz371a Prostate Cancer	Biozeus Biopharmaceutical S.A.	P2	CCC (50)
Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) Prostate Cancer	Zhongda Hospital	P2	CCC (50)
Dapagliflozin Prostate Cancer	Yung NA	P2	CCC (50)
Dentalfluoro Prostate Cancer	University Hospitals Cleveland Medical Center	P2	CCC (50)
Ezetimibe Prostate Cancer	Cedars-Sinai Medical Center	P2	CCC (50)
Florastamin Prostate Cancer	HTA Co., Ltd.	P3	CCC (50)
Fresh Frozen Plasma Prostate Cancer	Konkuk University Medical Center	P4	CCC (50)
Ifinatamab Deruxtecan Prostate Cancer	Merck Sharp & Dohme LLC	P3	CCC (50)
Inkmune Prostate Cancer	Inmune Bio, Inc.	P1/2	CCC (50)
qlh12016 Prostate Cancer	Qilu Pharmaceutical Co., Ltd.	P1/2	CCC (50)
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone Prostate Cancer	University of Chicago	P2	CCC (50)
ra223 Prostate Cancer	European Organisation for Research and Treatment of Cancer - EORTC	P3	CCC (50)
Radiopharmaceutical 18F-Jk-Psma-7 Prostate Cancer	ITEL Telecomunicazioni Srl	P3	CCC (50)
Rosuvastatin Prostate Cancer	Cedars-Sinai Medical Center	P2	CCC (50)
shr2554 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P2	CCC (50)
Simvastatin Prostate Cancer	Cedars-Sinai Medical Center	P2	CCC (50)
Urea Prostate Cancer	Robert Bok, MD, PhD	P2	CCC (50)
Zanzalintinib Prostate Cancer	Exelixis	P3	CCC (50)
Enoblituzumab Prostate Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (49)
Trametinib Prostate Cancer	OHSU Knight Cancer Institute	P2	CCC (49)
[18f]f-resca-rt4 Prostate Cancer	RenJi Hospital	P2/3	CCC (48)

Showing 151 to 200 of 482 assets

PreviousPage 4 of 10Next